Chardan downgraded Seres Therapeutics (MCRB) to Neutral from Buy with a $6 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics Reports Positive Q1 2025 Results
- Seres Therapeutics’ Positive Earnings Call: Progress and Challenges
- Seres Therapeutics Advances SER-155 Program with FDA Submission
- Seres Therapeutics reports Q1 EPS $3.75, consensus $1.97
- MCRB Earnings Report this Week: Is It a Buy, Ahead of Earnings?